Name Targets Phase Company
pan-JAKs inhibitors      
Ruxolitinib / INCB-18424, INC-424 JAK1, JAK2, JAK3 2011 Filed Incyte
Tasocitinib / tofacitinib, CP-690550 JAK1, JAK2, TYK2 2012 Filed Pfizer
Baricitinib/ INCB-28050, LY-3009104 JAK1, JAK2 Phase III Incyte
GLPG-0634 JAK1, JAK2 Phase II Galapagos
CYT-387 JAK1, JAK2, TYK2 Phase II Cytopia
AT-9283 JAK2, JAK3, BCR-ABL Phase II Astex
INCB-16562 JAK1, JAK2 Preclinical Incyte
Selective JAK2 inhibitors      
Pacritinib/ SB-1518 JAK2/FLT3 Phase III S*Bio
Lestaurtinib / CEP-701 JAK2/PDGFR Phase III Caephalon
AZD-1480 JAK2 Phase II AstraZeneca
SAR-302503/ TG-101348 JAK2/RET Phase II Sanofi-Aventis
LY-2784544 JAK2 Phase II Lilly
BMS-911453 JAK2 Phase I Bristol-Myers Squibb
NS-018 JAK2 Phase I Nippon Shinyaku
TG02/ SB-1317 JAK2/CDK, FLT3 Phase I S*Bio
SB-1578 JAK2/FLT3 Phase I S*Bio
XL-019 JAK2 Phase I (Termination) Exelixis
AG-490 JAK2 Tools
compounds
No company
Selective JAK3 inhibitors      
R-348 JAK3 Phase I Rigel
VX-509 JAK3 Phase I Vertex
NC-1153 JAK3 Preclinical Texas Uni.
Table 1: Investigation of JAKs inhibitors.